A new comprehensive health platform company will focus on elevating value-based care capabilities with providers, payers, healthcare systems, and ACOs.
Rajesh Shrestha,
Intermountain Healthcare is forming a new value-based care company.
Called Castell, the company will offer a comprehensive platform of tools and services to support practice transformation and improvement. These resources will help all parts of the health ecosystem promote wellness for patients and excel within a value-based healthcare world.
“Intermountain has actively developed tools and initiatives to help providers and others successfully implement value-based care for years,” says Rajesh Shrestha, president and CEO of Castell. “Castell is one part of that work that we’re excited to officially share now."
Related article: Intermountain Healthcare, deCODE Launch Largest DNA Mapping Project in United States
The new company will offer a comprehensive platform of tools and services to support transformation and improvement:
“We continually see that without the right level of support, it is difficult for providers, health systems, payers, and others to thrive in a value-based healthcare world,” Shrestha says. “Intermountain’s day-to-day frontline experience and success in value-based care management programs make us uniquely prepared to extend our services to others through Castell. We are energized by this opportunity to simplify value-based care and help set the direction for the healthcare of the future.”
2023 Drug Trend Report - Xevant
May 16th 2024To effectively navigate the changing pharmacy landscape and maintain a robust, cost-effective pharmacy benefit, you must understand the forces behind rising drug trend. What’s driving your costs and what can you do about it? As a leader in the PBM analytics space, we offer a unique perspective on pivotal trend drivers. Here’s what our comprehensive analysis revealed: -A surge in utilization rates across specialty and non-specialty drugs, magnified by anti-obesity therapies -Financial strain imposed by anti-inflammatory biologics and the yet-to-be-fulfilled -promise of biosimilar savings -Persistent price inflation driving higher costs year over year
Read More